Blood levels of d-amino acids reflect the clinical course of COVID-19
© 2023 The Authors..
d-Amino acids, rare enantiomers of amino acids, have been identified as biomarkers and therapeutic options for COVID-19. Methods for monitoring recovery are necessary for managing COVID-19. On the other hand, the presence of SARS-CoV2 virus in the blood is associated with worse outcomes. We investigated the potential of d-amino acids for assessing recovery from severe COVID-19. In patients with severe COVID-19 requiring artificial ventilation, the blood levels of d-amino acids, including d-alanine, d-proline, d-serine, and d-asparagine, which were lower than the normal range before treatment, quickly and transiently increased and surpassed the upper limit of the normal range. This increase preceded the recovery of respiratory function, as indicated by ventilation weaning. The increase in blood d-amino acid levels was associated with the disappearance of the virus in the blood, but not with inflammatory manifestations or blood cytokine levels. d-Amino acids are sensitive biomarkers that reflect the recovery of the clinical course and blood viral load. Dynamic changes in blood d-amino acid levels are key indicators of clinical course.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Biochemistry and biophysics reports - 34(2023) vom: 05. Juli, Seite 101452 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kimura-Ohba, Shihoko [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 14.03.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.bbrep.2023.101452 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354150634 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354150634 | ||
| 003 | DE-627 | ||
| 005 | 20231226061612.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bbrep.2023.101452 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1180.xml |
| 035 | |a (DE-627)NLM354150634 | ||
| 035 | |a (NLM)36909453 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kimura-Ohba, Shihoko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Blood levels of d-amino acids reflect the clinical course of COVID-19 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Authors. | ||
| 520 | |a d-Amino acids, rare enantiomers of amino acids, have been identified as biomarkers and therapeutic options for COVID-19. Methods for monitoring recovery are necessary for managing COVID-19. On the other hand, the presence of SARS-CoV2 virus in the blood is associated with worse outcomes. We investigated the potential of d-amino acids for assessing recovery from severe COVID-19. In patients with severe COVID-19 requiring artificial ventilation, the blood levels of d-amino acids, including d-alanine, d-proline, d-serine, and d-asparagine, which were lower than the normal range before treatment, quickly and transiently increased and surpassed the upper limit of the normal range. This increase preceded the recovery of respiratory function, as indicated by ventilation weaning. The increase in blood d-amino acid levels was associated with the disappearance of the virus in the blood, but not with inflammatory manifestations or blood cytokine levels. d-Amino acids are sensitive biomarkers that reflect the recovery of the clinical course and blood viral load. Dynamic changes in blood d-amino acid levels are key indicators of clinical course | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 2D-HPLC, two-dimensional high-performance liquid chromatography | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a COVID-19, coronavirus disease 2019 | |
| 650 | 4 | |a Coronavirus disease 2019 (COVID-19) | |
| 650 | 4 | |a Recovery | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a SARS-CoV-2, severe acute respiratory syndrome coronavirus-2 | |
| 650 | 4 | |a Treatment | |
| 650 | 4 | |a d-Amino acid | |
| 700 | 1 | |a Takabatake, Yoshitsugu |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Atsushi |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Yoko |e verfasserin |4 aut | |
| 700 | 1 | |a Sakai, Shinsuke |e verfasserin |4 aut | |
| 700 | 1 | |a Isaka, Yoshitaka |e verfasserin |4 aut | |
| 700 | 1 | |a Kimura, Tomonori |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biochemistry and biophysics reports |d 2015 |g 34(2023) vom: 05. Juli, Seite 101452 |w (DE-627)NLM251624714 |x 2405-5808 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2023 |g day:05 |g month:07 |g pages:101452 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bbrep.2023.101452 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2023 |b 05 |c 07 |h 101452 | ||